Dendritic cells are the most powerful antigen-presenting cells playing a decisive role for the initiation and maintenance of primary immune responses. However, signaling pathways involved in the differentiation of these cells have not been fully determined. Imatinib is a novel tyrosine kinase inhibitor effective against Abl kinases, c-Kit, and plateletderived growth factor receptor. Using this compound, we show that human monocyte-derived dendritic cells generated in the presence of therapeutic concentrations of imatinib show a reduced expression of CD1a, MHC class I and II, and costimulatory molecules as well as decreased secretion of chemokines and cytokines resulting in an impaired capacity of dendritic cells to elicit primary T-cell responses. Using Western blot analyses, we found that these effects are mediated by inhibition of phosphatidylinositol 3-kinase/Akt pathways and a pronounced downregulation of nuclear localized protein levels of nuclear factor-KB family members. Importantly, using blocking antibodies and tyrosine kinase inhibitors, we show that the inhibitory effects of imatinib on dendritic cell differentiation are not mediated via platelet-derived growth factor receptor and c-Kit. Taken together, our study reveals that imatinib inhibits dendritic cell differentiation and function via Akt and nuclear factor-KB signal transduction. Importantly, we show that imatinib can inhibit the function of normal, nonmalignant cells that may result in immunosuppression of these patients.
INTRODUCTION
Dendritic cells are the most powerful antigen-presenting cells that play a crucial role for the initiation and maintenance of primary immune responses (1) . Dendritic cells acquire antigens in the periphery and migrate to the lymph nodes where antigen specific T lymphocytes recognize the presented peptide antigens (1 -3) . Tissue-resident dendritic cells originate from bone marrow -derived circulating precursors able to develop into antigen-capturing dendritic cells (1, 2) . In vitro, CD34 + progenitor cells can differentiate into dendritic cells after culture with different cytokine combinations, including granulocyte macrophage-colony-stimulating factor (GM-CSF), tumor necrosis factor-a, interleukin (IL)-4, Flt3 ligand, and stem cell factor. Alternatively, dendritic cells can be generated from CD14
+ peripheral blood monocytes using GM-CSF and IL-4 (1, 2, 4 -13). In a variety of immunotherapeutic approaches and in in vitro models, monocyte-derived dendritic cells (MDC) are used as antigen-presenting cells. Despite this broad application, the signal transduction pathways regulating the development and function of these cells have not yet been fully determined.
Imatinib (Glivec, Gleevec, STI571) is an ATP-competitive Bcr-Abl tyrosine kinase inhibitor that is also active against platelet-derived growth factor receptor (PDGF-R), c-Kit (14) , Abl-related gene, and their fusion proteins while probably not affecting other tyrosine kinases (15 -17) . In clinical trials, imatinib has shown promising results in the treatment of Philadelphia chromosome -positive chronic myelogenous leukemia (CML; refs. 18 -27) , acute lymphoid leukemia (28, 29) , and gastrointestinal stroma tumors (14, 15, 30 -34) that are characterized by activating mutations of c-Kit as well as myeloproliferative disorders with mutations in the gene encoding PDGF-Rh (35) .
In this study, we show that exposure of human CD14 + peripheral blood monocytes to therapeutic concentrations of imatinib during differentiation into dendritic cells affects their phenotype, cytokine secretion, and T-cell stimulatory capacity due to inhibition of nuclear factor-nB (NF-nB) and Akt signaling pathways. Dendritic Cell Generation. Dendritic cells were generated from peripheral blood adhering monocytes by either magnetic cell sorting or plastic adherence as described previously (7, 36, 37) . In brief, peripheral blood mononuclear cells were isolated by Ficoll/Paque (Biochrom, Berlin, Germany) density gradient centrifugation of blood obtained from buffy coats of healthy volunteers from the blood bank of the University of Tübingen. For magnetic cell sorting, CD14 + magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were used. For isolation of monocytes by plastic adherence, peripheral blood mononuclear cells were seeded (1 Â 10 7 per well) into six-well plates (BD Falcon, Heidelberg, Germany) in X-VIVO 20 medium (BioWhittaker, Apen, Germany). After 2 hours of incubation at 37jC and 5% CO 2 , nonadherent cells were removed and adherent monocytes were cultured in RP10 medium supplemented with GM-CSF (100 ng/mL, Leucomax, Novartis) and IL-4 (20 ng/mL, R&D Systems, Wiesbaden, Germany). Cytokines were added to differentiating dendritic cells every 2 to 3 days. Imatinib was dissolved in DMSO and added to the culture medium starting from the first day of culture together with GM-CSF and IL-4 in concentrations ranging from 1 to 5 Amol/L. To exclude effects induced by the solvent, equal amounts of DMSO were added as a control. In some experiments, dendritic cell maturation was induced by adding lipopolysaccharide (LPS, Sigma, Deisenhofen, Germany) at day 6 of culture. For blocking experiments, either antibodies or kinase inhibitors were added to the cells together with the cytokines. Antibodies used were directed against stem cell factor (mouse monoclonal, 1 Ag/mL, R&D Systems), c-Kit (mouse monoclonal, 10 Ag/ mL, Sigma), PDGF, PDGF-Ra, and PDGF-Rh (all goat polyclonal, 10 Ag/mL, R&D Systems). Mouse IgG (Dianova, Hamburg, Germany) was added to control cells. Kinase inhibitors used were phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin (100 nmol/L, Sigma), Src kinase inhibitor PP1, PDGF-R kinase inhibitor tyrphostin AG1296, and c-Abl kinase inhibitor AG957 adamantyl ester (all Calbiochem, Schwalbach, Germany). Because the substances were dissolved in DMSO, equal amounts of DMSO were added to control cells.
MATERIALS AND METHODS
Immunostaining. Cells were stained using FITC-or phycoerythrin-conjugated mouse monoclonal antibodies against CD14, CD80, HLA-DR, CD3, CD11c, CD19, and CD54 (BD Biosciences, Heidelberg, Germany); CD33, CD40, and CD86 (BD PharMingen, Hamburg, Germany); CD1a, CD11a, and HLA-ABC (DAKO Diagnostika GmbH, Hamburg, Germany); CD83 (Immunotech, Marseilles, France); CCR7 (R&D Systems), and mouse IgG isotype control (BD Biosciences). Cells were analyzed on a FACSCalibur cytometer (BD Biosciences). A proportion of 1% false-positive events was accepted in the negative control samples. Staining was carried out in at least three independent experiments.
Detection of Apoptosis. For detection of apoptosis, the Annexin V-Fluos Staining kit (Roche Diagnostics GmbH, Mannheim, Germany) was used according to the instructions of the manufacturer in two independent experiments. Cytokine Determination. Cytokine concentrations in supernatants from dendritic cell cultures were measured with commercially available two-site sandwich ELISA from R&D Systems (Rantes, monocyte chemoattractant protein-1, macrophage inflammatory protein-1a) and Beckman Coulter (Hamburg, Germany; IL-12, tumor necrosis factor-a, IL-6) according to the manufacturer's instructions. Determination of cytokine and chemokine secretion was carried out in at least three independent experiments.
Induction of Antigen-Specific CTL Response Using the HLA-A2-Restricted Peptide E75 from HER-2/neu. The induction of HER-2/neu-specific CTL was done as described previously (36, 37) . The HLA-A2 binding peptide derived from HER-2/neu E75 (369-377, KIGSFLAFL) and HIV (pol HIV-1 reverse transcriptase peptide, amino acids 476-484, ILKEPVHGV) were synthesized using standard Fmoc chemistry on a peptide synthesizer (432A, Applied Biosystems, Weiterstadt, Germany) and analyzed by reversed-phase highperformance liquid chromatography and mass spectrometry. For CTL induction, 5 Â 10 5 dendritic cells were pulsed with 50 Ag/mL E75 peptide for 2 hours, washed, and incubated with 3 Â 10 6 autologous peripheral blood mononuclear cells without imatinib. After 7 days of culture, cells were restimulated with autologous peptide-pulsed peripheral blood mononuclear cells, and 2 ng/mL IL-2 (R&D Systems) was added on days 1, 3, and 5. Cytolytic activity of induced CTL was analyzed on day 5 after the last restimulation in a standard 51 Cr release assay. CTL Assay. The standard 51 Cr release assay was done as described previously (7, 36, 37) . Target cells were pulsed with 50 Ag/mL peptide for 2 hours and labeled with 51 Cr sodium chromate (Amersham Biosciences Europe, Freiburg, Germany) for 1 hour at 37jC. Cells (1 Â 10 4 ) were transferred to a well of a round-bottomed 96-well plate. Varying numbers of CTLs were added to a final volume of 200 AL and incubated for 4 hours at 37jC. At the end of the assay, supernatants (50 AL/well) were harvested and counted in a h-plate counter. The percentage of specific lysis was calculated as (experimental release À spontaneous release/maximal release À spontaneous release) Â 100. Spontaneous and maximal releases were determined in the presence of either medium or 2% Triton X-100, respectively.
PAGE and Western Blotting. Nuclear extracts were prepared from dendritic cells as described previously (38, 39) . For the preparation of whole cell lysates, cells were lysed in a buffer containing 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 2 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 2 Ag/mL aprotinin, and 1 mmol/L sodium orthovanadate. Protein concentrations of protein lysates were determined using a BCA assay (Pierce, Perbio Science, Bonn, Germany). For the detection of nuclear localized NF-nB family members, f20 Ag of nuclear extracts were separated on a 10% SDS-PAGE gel and transferred onto nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). Ponceau S staining of the membrane was done to confirm that equal amounts of protein were present in every lane. Incubation of all primary antibodies was followed by incubation with an appropriate horse radish peroxidaseconjugated secondary antibody. Bands were visualized by enhanced chemiluminescence staining (Amersham Bio sciences Europe).
Western blotting was carried out in at least three independent experiments.
High-Density Oligonucleotide Microarray Analysis. Total RNA from dendritic cells generated in the presence or absence of 3 Amol/L imatinib was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer. Double-stranded cDNA was synthesized from 6 Ag total RNA using SuperScript RTII (Invitrogen) and the primer (MWG Biotech, Ebersberg, Germany) according to the Affymetrix manual as described previously (40) . In vitro transcription using the BioArray High-Yield RNA Transcript Labeling kit (ENZO Diagnostics, Inc., Farmingdale, NY), fragmentation, hybridization on Affymetrix U133A GeneChips (Affymetrix, Santa Clara, CA), and staining with streptavidinphycoerythrin and biotinylated anti-streptavidin antibody (Molecular Probes, Leiden, the Netherlands) followed the manufacturer's protocols (Affymetrix). The Affymetrix GeneArray Scanner was used and data were analyzed with the Microarray Analysis Suite 5.0. For normalization, 100 housekeeping genes provided by Affymetrix were used (http:// www.affymetrix.com/support/technical/mask_files.affx). Pairwise comparisons of dendritic cells generated in the presence versus absence of imatinib were calculated. Significance of differential expression was judged by the ''change'' values given by the statistical algorithms implemented in the Microarray Analysis Suite 5.0. For a gene to be considered as upregulated or down-regulated, the following criteria had to be met: ''increase'' or ''decrease'' in the ''change'' value and presence in the ''detection algorithm'' in the sample with the higher expression. The complete experiment was done in duplicates.
Analysis of Phagocytic and Endocytic Capacity. For the analysis of phagocytic and endocytic activity, 2 Â 10 5 cells were incubated with 3.4 Â 10 7 FITC-labeled carboxylatemodified latex beads (1 Am, Sigma) or FITC-dextran (40,000 molecular weight, Molecular Probes-Invitrogen) for 1 hour at 37jC. As a control, 2 Â 10 5 cells were precooled to 4jC before the incubation with latex beads or dextran at 4jC for 1 hour. (Fig. 1 ). This effect was also observed when imatinib was added to the medium of GM-CSF/IL-4 generated MDCs on day 4 of culture ( Fig. 1 ). The expression of CD11a, CD11c, and CD33 was not affected (data not shown). Moreover, the phenotypic changes were not reversible, because additional culturing of the MDCs for 5 days without imatinib did not reestablish the expression of CD1a (data not shown). Importantly, the effects of imatinib were not caused by induction of apoptosis as analyzed by Annexin V and propidium iodide staining (Fig. 2) . Imatinib Inhibits Dendritic Cell Maturation. To evaluate the responsiveness of the MDCs generated in the presence of imatinib to a maturation stimulus, we added LPS 24 hours before harvesting the cells. In GM-CSF/IL-4-generated MDCs, this resulted in the up-regulation of the maturation marker CD83 as well as costimulatory molecules CD86, CD80, CD40, adhesion molecule CD54, and high expression levels of HLA-ABC and HLA-DR (Fig. 3) . However, most of these molecules were not up-regulated in the presence of 3 Amol/L imatinib added from the first day of culture (Fig. 3) . Similar effects on the expression of dendritic cell surface markers were observed when the medium was supplemented with imatinib after 4 days of culture (Fig. 3) .
Imatinib Modulates Cytokine and Chemokine Secretion of Dendritic Cells. Secretion of cytokines and chemokines known to be important for dendritic cell function was analyzed by ELISA. Exposure of differentiating MDCs to imatinib inhibited monocyte chemoattractant protein-1 (CCL2) secretion while not affecting Rantes (CCL5), IL-6, or tumor necrosis factor-a production (Table 1) . Dendritic cells differentiated in the presence of 3 Amol/L imatinib and stimulated with LPS showed a reduction of monocyte chemoattractant protein-1 (CCL2), Rantes (CCL5), macrophage inflammatory protein-1a (CCL3), and IL-12 secretion, whereas the production of tumor necrosis factor-a, IL-10, and IL-6 was not altered (Table 2; data not shown). These inhibitory effects were also observed when imatinib was added on day 4 to the culture medium (Table 2) .
Exposure to Imatinib Reduces the Capacity of Dendritic Cells to Initiate Specific Lymphocyte Responses. The induction of primary immune responses is a unique feature of dendritic cells. Therefore, we analyzed the ability of dendritic cells generated from adherent peripheral blood monocytes in the presence of GM-CSF and IL-4 with or without imatinib to initiate primary CTL responses. To accomplish this, MDCs were pulsed with the synthetic HLA-A2 binding peptide E75 derived from HER-2/neu tumor associated antigen and used as antigen-presenting cells. After two weekly restimulations, the CTL lines showed peptide specific and HLA-A2 restricted killing of tumor cell lines pulsed with the cognate peptide (Fig. 4A ). This was also true for tumor cell lines constitutively expressing the HER-2/neu antigen (data not shown). Dendritic cells generated in the presence of 3 Amol/L imatinib failed to elicit antigen specific CTL responses (Fig. 4B ). To ensure that this effect was not solely due to a reduced IL-12 secretion by MDCs treated with imatinib (Table 2) , IL-12 was added during CTL priming. However, IL-12 supplementation did not restore the capacity of MDCs generated in the presence of imatinib to induce a primary CTL response ( Fig. 4C and D) .
The inhibitory effect of imatinib on the stimulatory capacity of dendritic cells was not due to an increased IL-10 secretion as analyzed by a commercially available ELISA (data not shown).
A Multitude of Genes Are Regulated by Imatinib. To further analyze which molecules and pathways are affected by imatinib and are probably involved in the observed inhibitory effects, we did comparative expression profiling using DNA microarray technology. Table 3 shows a selection of genes upregulated in dendritic cells treated with imatinib. Interestingly, most of the genes overexpressed after treatment of the cells with imatinib represent lysosomal proteins or molecules known to be primarily expressed in monocytes/macrophages, confirming the results obtained from the phenotypic analyses and indicating that imatinib inhibits the differentiation of monocytes into dendritic cells. Based on the results derived from gene expression and phenotype analysis, we sought to determine the phagocytic and endocytic capacity of the generated cell populations. To test this, we incubated the cells with FITC-labeled latex beads or FITC-labeled dextran for 1 hour at 37jC and 4jC. None of the cell populations were able to incorporate significant amounts of latex beads (data not shown). As shown in Fig. 5A , FITC-dextran accumulated in immature dendritic cells incubated at 37jC, whereas the control cells incubated at 4jC did not take up the dextran. Treatment of immature dendritic cells with 3 Amol/L imatinib resulted in a reduction of FITC-dextran uptake. As expected, mature dendritic cells stimulated with LPS only scarcely internalized FITC-dextran (Fig. 5B) .
Imatinib Down-Regulates Nuclear Factor-KB Transcription Factor Family Members. Recently, it was shown that different members of the NF-nB family of transcription factors are important for the differentiation and function of dendritic cells (41 -46) . Therefore, we evaluated the nuclear localization of RelA, RelB, c-Rel, and NF-nB p50 proteins in the generated dendritic cell populations. Western blot analysis revealed that the amount of nuclear localized RelB (Fig. 6A) , RelA (Fig. 6B) , c-Rel (Fig. 6C) , and NF-nB p50 (Fig. 6D ) and the induction of these molecules by maturation stimuli is reduced in dendritic cells generated in the presence of 3 Amol/L imatinib added either from the first day of culture or on day 4. These results suggest that the effects of imatinib are mediated at least in part by inhibition of NF-nB signaling pathways.
Imatinib Affects Phosphatidylinositol 3-Kinase Pathway. Regulation of NF-nB expression and function involves several pathways, including the mitogen-activated protein kinase and PI3K. To examine this, Western blot analyses and specific kinase inhibitors were used to determine the possible involvement of these pathways in the inhibitory effects of imatinib. Using a phosphospecific antibody against Akt, concentration-dependent decrease of phosphorylation was observed (Fig. 7A) . In contrast, we did not detect any differences in the phosphorylation state of p38 and extracellular signal-regulated kinase 1 (data not shown). To confirm that PI3K pathways are involved in the inhibitory effects imatinib has on the development and function of dendritic cells, PI3K inhibitor wortmannin was added to the cells starting from the first day of culture. The addition of this compound had a similar effect on dendritic cell phenotype as imatinib as analyzed by fluorescence-activated cell sorting staining (Fig. 7B) .
Effect of Imatinib on Dendritic Cell Differentiation Is Not Mediated by c-Kit and Platelet-Derived Growth Factor
Receptor. Besides Bcr-Abl, imatinib inhibits c-Kit and PDGF-R associated kinases. To analyze which tyrosine kinase is possibly involved in the observed inhibition of dendritic cell function, we did blocking experiments using neutralizing antibodies shown to be active as described previously (39, 47) . Incubation of blood monocytes with antibodies against stem cell factor and its receptor c-Kit or antibodies against PDGF, PDGF-Ra, and PDGF-Rh had no effect on dendritic cell development as analyzed by flow cytometry (data not shown), indicating that c-Abl inhibition is probably involved in the observed alterations in dendritic cell phenotype and function. In the next set of experiments, we therefore used other tyrosine kinase inhibitors known to inhibit signaling mediated by the above-mentioned tyrosine kinases. As shown in Fig. 8A and B, addition of c-Abl inhibitor AG957 and Src kinase inhibitor PP1, which also inhibits c-Kit, PDGF-R, and c-Abl (48), had similar effects on dendritic cell phenotype as shown for CD1a expression on dendritic cells as imatinib. Interestingly, incubation of peripheral blood monocytes with PDGF-R kinase inhibitor tyrphostin AG1296 did not significantly reduce the CD1a expression on dendritic cells, confirming that the effects of imatinib are not mediated by PDGF-R.
DISCUSSION
Although MDCs are extensively used as antigen-presenting cells in in vitro models and in a variety of immunotherapeutic approaches, signaling pathways mediating or affecting their differentiation have not been fully determined.
In our previous expression studies by reverse transcription-PCR, we found that PDGF-Rh as well as its ligands are expressed in human MDCs (data not shown). Therefore, we used the specific *Gene symbols and names refer to LocusLink (http://www. ncbi.nlm.nih.gov/LocusLink/); whenever possible, symbols approved by the HUGO Gene Nomenclature Committee were used.
yRefSeqs are reference sequence standards provided by the National Center for Biotechnology Information. tyrosine kinase inhibitor imatinib to block this pathway during dendritic cell development in vitro. Imatinib is an ATPcompetitive inhibitor of c-Kit, PDGF-R, Abl-related gene, and c-Abl as well as its fusion proteins, although it has no effects on other tyrosine kinases. Due to this selective inhibition, imatinib is currently used in the treatment of human malignancies caused by mutations resulting in an uncontrolled activation of these tyrosine kinases. Imatinib was shown to be very effective when applied to patients with CML, Philadelphia chromosome -positive acute lymphoid leukemia, or gastrointestinal stroma tumor by inducing a high rate of objective clinical responses with limited nonhematologic toxicity.
In our study, addition of imatinib to the medium in concentrations varying from 1 to 5 Amol/L, serum levels typically achieved in patients (18) , resulted in the reduced expression of cell surface molecules known to be up-regulated or induced during the differentiation of monocytes into dendritic cells (like MHC class I and II or costimulatory molecules) or represent dendritic cell -associated antigens like CD1a. The same effects were observed when imatinib was added after 4 days of culture, demonstrating that imatinib can also affect already differentiated dendritic cells. Interestingly, imatinib did not influence the viability of the cells as analyzed by Annexin V staining.
Further analysis of the functional capabilities of the cells generated in the presence of imatinib revealed that these cells showed an impaired ability to initiate primary T-cell responses and a reduced secretion of cytokines and chemokines induced on stimulation with LPS. This indicates that the inhibition of the functional properties of dendritic cells by imatinib is a result of down-regulated expression of MHC and costimulatory molecules and decreased activation-induced production of cytokines and chemokines involved in T-cell stimulation.
In the next set of experiments, we extended our analyses of the involved molecules and pathways by applying the DNA microarray technology. In these experiments, we found that treatment of cells with imatinib leads to up-regulation of lysosomal proteins and molecules primarily expressed in monocytes/macrophages. Therefore, we determined the phagocytic and endocytic capacity of the generated cell populations. Although no effect on the phagocytosis rate as analyzed by latex beads uptake could be detected, immature dendritic cells incubated with 3 Amol/L imatinib had a reduced capacity to internalize FITC-dextran.
Interestingly, we also detected an increased expression of peroxisome proliferative-activated receptor-g in imatinib-treated cells. Peroxisome proliferative-activated receptor-g is a member of the nuclear hormone receptor superfamily, which are largely involved in the control of lipid metabolism and energy balance. Activation of peroxisome proliferative-activated receptor-g by its ligands, the cyclopentenone prostaglandins of the J series, results in the inhibition of dendritic cell function (49, 50) .
To further investigate the pathway of imatinib-mediated effects, we analyzed the nuclear localization of members of the NF-nB family known to be critically involved in dendritic cell differentiation and function. The Rel/NF-nB family of transcription factors regulates a broad variety of genes during immune responses (51) and has been shown to be essential for efficient antigen presentation by dendritic cells (41 -46, 52 -54) . Activation of NF-nB is a complex process involving the phosphorylation of inhibiting InB proteins by the InB kinase complex resulting in the nuclear translocation of NF-nB. Mice with gene deletions of different NF-nB family members have helped to delineate their individual physiologic role (41, 55, 56) . In vitro studies as well as RelB À/À mice showed that RelB is an important factor in dendritic cell function and development, as RelB À/À mice have no apparent myeloid dendritic cells (46). We described previously in line with the results from animal studies that RelB and c-Rel are involved or associated with the secretion of cytokines like IL-12 and the ability of dendritic cells to stimulate T cells (37) . In the present study, we found by Western blot analyses a reduction of nuclear localized RelB in cells generated in the presence of imatinib and decreased activation induced up-regulation of RelB, RelA, c-Rel, and NF-nB p50, demonstrating that imatinib mediates its effects at least in part via the NF-nB pathway. In line with these results, we observed that the presence of imatinib during dendritic cell generation reduced phosphorylation of Akt, which is a kinase involved in diverse pathways activating NF-nB (57 -61) . Moreover, PI3K inhibitor wortmannin had similar effects on dendritic cell phenotype as imatinib, confirming the involvement of this pathway.
In accordance with our results, it was shown recently by Dietz et al. that imatinib inhibits T-cell functions by affecting the NF-nB signaling pathway (62) . Furthermore, the authors found that these inhibitory effects were accompanied by a diminished phosphorylation of extracellular signal-regulated kinase 1/2, which is in contrast to our results. However, higher concentrations of imatinib (10 Amol/L) were used in this study and analysis was done at earlier time points. In addition, these findings might reflect the use of different pathways in distinct cell populations.
In the next set of experiments, we tried to delineate which receptor tyrosine kinase might mediate the phenotypical and functional alterations induced by imatinib. Therefore, we first used blocking antibodies against c-Kit and its ligand stem cell factor as well as antibodies inhibiting all PDGFs and both receptors, PDGF-Ra and PDGF-Rh. However, addition of these antibodies to the cell culture had almost no influence on dendritic cell phenotype, suggesting that the above-described effects of imatinib are probably mediated by inhibition of c-Abl or via other as yet unknown signaling cascades.
We next took advantage of other tyrosine kinase inhibitors: c-Abl-specific inhibitor AG957; PP1, a Src kinase inhibitor that also inhibits PDGF-R, c-Kit, and c-Abl tyrosine kinase (48) ; and tyrphostin AG1296, a selective inhibitor of PDGF-R. By applying these molecules, we found that AG957 and PP1, like imatinib, inhibits the up-regulation of CD1a in a concentrationdependent manner, whereas tyrphostin AG1296 had only marginal effect on dendritic cell phenotype, supporting the results from the experiments with the blocking antibodies.
We and others have shown previously that imatinib can act on normal CD34 + progenitor cells (47) and inhibit their development into dendritic cells (39) . In contrast to monocytes and MDCs, CD34 + cells express c-Kit and stem cell factor, both of which have been shown to be important for the development of dendritic cells from human progenitor cells. However, in this study, we found that c-Kit is not significantly involved in the effects induced by imatinib. In contrast to the experiments with MDCs, we found that in CD34 + -derived dendritic cells imatinib only inhibited the up-regulation of RelB while not affecting RelA or c-Rel, indicating that the signal transduction pathways may be different in these cell populations.
In contrast to our findings, Sato et al. showed that antigen presentation of dendritic cells from CML patients is restored by addition of imatinib (63) . However, Bcr-Abl-positive dendritic cells are functionally defective and differ from normal dendritic cells.
According to our results, c-Abl inhibition might be involved in the inhibitory effects of imatinib on dendritic cell function and differentiation. Although it is well analyzed that activated c-Abl has generally growth stimulatory and antiapoptotic effects, not much is known about the complex physiologic function of this nonreceptor tyrosine kinase in spite of multiple potential roles according to the functional domains of the protein. Studies in c-Abl knockout mice have shown that homozygous deletion of either the whole protein (64) or the COOH-terminal one-third (65) leads to neonatal lethality and Bcell and T-cell lymphopenias while not affecting myeloid or erythroid lineages. However, the development and function of dendritic cells in these animals were not analyzed. A more recent study has shown that c-Abl À/À mice are osteoporotic due to defects in maturation of osteoblasts (66) . In normal cells, involvement of c-Abl in cell division, cell differentiation, cell adherence, cell death, cell mobility, and integrin receptormediated signal transduction is likely (67 -70) .
In conclusion, we show that c-Abl tyrosine kinase might play an important role in the differentiation and function of MDCs and that imatinib mediates its effects at least in part via NF-nB and PI3K/Akt kinase signal transduction pathways. Another important observation is that imatinib, a drug used in the treatment of patients with malignant diseases, can affect the function of normal, nonmalignant cells and might therefore result in immunosuppression in these patients. This is important as some of the therapeutic effects in the treatment of patients with CML are mediated by the induction of leukemia specific T-cell responses and imatinib is currently applied in the combination with allogeneic stem cell transplantation. This assumption is supported by the recent observation that the induction of myeloblastinspecific T cells is impaired in CML patients treated with imatinib in contrast to patients receiving IFN-a (71). Furthermore, mice treated with imatinib show a reduced Flt3 ligand-mediated expansion of dendritic cells and antitumor activity (72) as well as diminished delayed-type hypersensitivity responses in vivo (62) . Moreover, several reports have been published that support the assumption of imatinib being immunosuppressive. Mattiuzzi et al. described that treatment of CML patients with imatinib is associated with an increased risk of herpes zoster infection (73) . Other studies observed the induction of EBV-positive B-cell lymphoma (74) , pulmonary alveolar proteinosis (75) , and remission of rheumatoid arthritis (76) in CML patients during therapy with imatinib.
Taken together, our study shows that the inhibitory effects of imatinib on dendritic cell differentiation and function are mediated via Akt and NF-nB signaling pathways. Moreover, we show that imatinib can affect normal, nonmalignant cells, which may result in immunosuppression of patients treated with this drug.
